Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Filtration Technology Steps Up to Next Level
Bioprocessors' Evolving Separation Needs Continue to Fuel Innovative Approaches
- Process streams look very different from five or ten years ago, states Jean Paul Mangeolle, president of Millipore’s (www.millipore.com) bioprocess division. Rising protein titers have caused many processes to shrink, but more concentrated process fluids strain downstream operations designed for more dilute process streams. “Yesterday’s 20,000-liter tank is now ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.